Amendment 006.pdf

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE PAGE OF PAGES

1 1

2. AMENDMENT/MODIFICATION NO.

3. EFFECTIVE DATE

See Block 16C

4. REQUISITION / PURCHASE REQ. NO. PROJECT NO. (If Applicable)

6. ISSUED BY

Federal Bureau of Prisons 200 Chestnut Street US Custom House, 7th Floor Philadelphia, PA 19106

CODE 7. ADMINISTERED BY (If other than Item 6) CODE

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

(√) 9A. AMENDMENT OF SOLICITATION

NO RFP 15BRRC21R00000354√

9B. DATED (See Item 11)

09/21/2021

10A. MODIFICATION OF CONTRACT/ORDER NO.

CODE FACILITY CODE 10B. DATED (See Item 13)

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

[X ] The above number solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers [X] is extended, [ ] is not extended.

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods.

(a) By completing Items 8 and 15, and returning 1 copy of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OR CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

A. THE CHANGE ORDER IS ISSUED PURSUANT TO: (Specify Authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM

14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor [ ] is not [ x ] is required to sign this document and return 1 copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible).

RFP 15BRRC21R00000354 located in Raleigh, North Carolina is hereby amended as follows:

1. Extend the closing date from January 21, 2022 to January 28, 2022.

2. Incorporate the updated Department of Labor Wage Determination 1995-0607 Rev No. 51 dated 12-27-21 (see attached).

3. Remove and replace the Attachment H that was incorporated via Amendment 001 with the revised version (see attached).

Except as provided herein, all items and conditions of the document referenced in item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

Kevin Hoff

15B. CONTRACTOR/OFFEROR

(Signature of person authorized to sign)

15C. DATE SIGNED 16B. UNITED STATES OF AMERICA

BY //s// (Signature of Contracting Officer)

16C. DATE SIGNED

01/20/2022

STANDARD FORM 30 (REV. 11/2016)

PREVIOUS EDITION UNUSABLE Prescribed by GSA FAR (48 CFR) 53.243

����������!"#$%&'#"�()�*+$#�,#'#"-%.+'%(.&�/.,#"��0��������/1&1�,#2+"'-#.'�()�3+4("����������������'5#�&#"6%7#�7(.'"+7'�+7'��������0��#-23(8-#.'�&'+.,+",&�+,-%.%&'"+'%(.����49�:;<=>?;@A�@B�?C=�&=><=?D<9�@B�3DE@<�0���������*+$#�+.,�5(/"�,%6%&%(.�������������������������������������������������0���������*+&5%.$'(.�,171��FGFHG�������������������������������������������������0����������������������������������������0����������������������������������������0����������������������������������������0�*DI=�,=?=<J;AD?;@A�.@1K�HLLMNGOGP�,DA;=Q�*1�&;JJR����������,;S;R;@A�@B���0�����������"=S;R;@A�.@1K�MH�,;<=>?@<������������*DI=�,=?=<J;AD?;@AR0��,D?=�(B�3DR?�"=S;R;@AK�HFTFPTFGFH�UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU0UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU�.@?=K�7@A?<D>?R�RVEW=>?�?@�?C=�&=<S;>=�7@A?<D>?�+>?�D<=�I=A=<DQQ9�<=XV;<=:�?@��YD9�D?�Q=DR?�?C=�DYYQ;>DEQ=�J;A;JVJ�ZDI=�<D?=�<=XV;<=:�VA:=<�#[=>V?;S=�(<:=<��H\GFO�@<�#[=>V?;S=�(<:=<�H]OM̂1��%B�?C=�>@A?<D>?�;R�=A?=<=:�;A?@�@A�@<�DB?=<�_DAVD<9�]G�FGFF�@<�?C=�>@A?<D>?��;R�<=A=Z=:�@<�=[?=A:=:�̀=1I1�DA�@Y?;@A�;R�=[=<>;R=:a�@A�@<�DB?=<�_DAVD<9�]G��FGFF�#[=>V?;S=�(<:=<�H\GFO�I=A=<DQQ9�DYYQ;=R�?@�?C=�>@A?<D>?1��'C=�>@A?<D>?@<��JVR?�YD9�DQQ�>@S=<=:�Z@<b=<R�D?�Q=DR?�cHM1GG�Y=<�C@V<�̀@<�?C=�DYYQ;>DEQ=�ZDI=��<D?=�Q;R?=:�@A�?C;R�ZDI=�:=?=<J;AD?;@A�;B�;?�;R�C;IC=<a�B@<�DQQ�C@V<R�RY=A?��Y=<B@<J;AI�@A�?CD?�>@A?<D>?�;A�FGFF1�%B�?C=�>@A?<D>?�ZDR�DZD<:=:�@A�@<�E=?Z==A�_DAVD<9�H�FGHM�DA:�_DAVD<9�FL�FGFF��DA:�?C=�>@A?<D>?�;R�A@?�<=A=Z=:�@<�=[?=A:=:�@A�@<�DB?=<�_DAVD<9�]G�FGFF��#[=>V?;S=�(<:=<�H]OM̂�I=A=<DQQ9�DYYQ;=R�?@�?C=�>@A?<D>?1��'C=�>@A?<D>?@<�JVR?��YD9�DQQ�>@S=<=:�Z@<b=<R�D?�Q=DR?�cHH1FM�Y=<�C@V<�̀@<�?C=�DYYQ;>DEQ=�ZDI=�<D?=��Q;R?=:�@A�?C;R�ZDI=�:=?=<J;AD?;@A�;B�;?�;R�C;IC=<a�B@<�DQQ�C@V<R�RY=A?��Y=<B@<J;AI�@A�?CD?�>@A?<D>?�;A�FGFF1�'C=�DYYQ;>DEQ=�#[=>V?;S=�(<:=<�J;A;JVJ�ZDI=�<D?=�Z;QQ�E=�D:WVR?=:�DAAVDQQ91��+::;?;@ADQ�;AB@<JD?;@A�@A�>@A?<D>?@<�<=XV;<=J=A?R�DA:�Z@<b=<�Y<@?=>?;@AR�VA:=<��?C=�#[=>V?;S=�(<:=<R�;R�DSD;QDEQ=�D?�ZZZ1:@Q1I@STZC:TI@S>@A?<D>?R1�UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU�&?D?=K�.@<?C�7D<@Q;AD��+<=DK�.@<?C�7D<@Q;AD�7@VA?;=R�@B�4=<?;=�,V<CDJ�#:I=>@JE=�)<DAbQ;A��$<DAS;QQ=�5DQ;BD[�5=<?B@<:�.DRC�.@<?CDJY?@A�(<DAI=�2=<R@A�6DA>=�*Db=��*D<<=A�UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU�

����������!!"#$%&'�('%')$*+�,'-.$#'/�"01102�*3'�455.67*$0%71�8$+*$%&!!�����������499:;<=>4?�94@A�B�=>=8A����������������������������������"44=?4=A���������������,<=A�"00/�C�80/&$%&D���EFEGH�B�900I�>���������������������������������������������������������������HJKFL���EFEGJ�B�900I�>>��������������������������������������������������������������HMKHG���EFEFE�B�@$+327+3'#������������������������������������������������������������LKFM���EFHNE�B�"00/�O'#P$5'�Q0#I'#��������������������������������������������������HEKGH���EFJRE�B�Q7$*'#SQ7$*#'++�������������������������������������������������������LKFM���HHERE�B�A1'P7*0#�46'#7*0#�����������������������������������������������������LKFM���HHJHE�B�87T0#'#�U#0.%/+�V7$%*'%7%5'�����������������������������������������HEKGH���HHJGE�B�V7$/�0#�W0.+'X7%�����������������������������������������������������HEKGH���LLENE�B�97+3$'#��������������������������������������������������������������HEKGH���LLEME�B�@'+I�91'#I�������������������������������������Y+''�HZ���������������HEKGH�W71)27[�W0.+'�C�,'+$/'%*$71�90XX.%$*[�=#'7*X'%*D���EHEHH�B�<550.%*$%&�91'#I�>���������������������������������������������������HJKHF���EHEHJ�B�<550.%*$%&�91'#I�>>��������������������������������������������������HNKEH���EHHHH�B�U'%'#71�91'#I�>������������������������������������������������������HHKNR���EHNHH�B�O'5#'*7#[�>����������������������������������������������������������HNKLH���EHRHH�B�Q0#/�;#05'++0#�>�����������������������������������������������������HHKNR���EFEGH�B�900I�>���������������������������������������������������������������HJKFL���EFEGJ�B�900I�>>��������������������������������������������������������������HMKHG���EFEFE�B�@$+327+3'#������������������������������������������������������������LKFM���EFHNE�B�"00/�O'#P$5'�Q0#I'#��������������������������������������������������HEKGH���HHHME�B�\7%$*0#��������������������������������������������������������������HEKGH���HHJHE�B�87T0#'#�U#0.%/+�V7$%*'%7%5'�����������������������������������������HEKGH���HHJGE�B�V7$/�0#�W0.+'X7%�����������������������������������������������������HEKGH���JNNFE�B�U'%'#71�V7$%*'%7%5'�Q0#I'#�������������������������������������������HNKMF���JFHEH�B�U.7#/�>��������������������������������������������������������������HHKNJ���JFHEJ�B�U.7#/�>>�������������������������������������������������������������HJKEM���LLEME�B�@'+I�91'#I�������������������������������������Y+''�HZ���������������HHKNR�V0P$%&�C�O*0#7&'D���JHEJE�B�"0#I1$)*�46'#7*0#����������������������������������������������������HJKFL���JHEME�B�V7*'#$71�W7%/1$%&�87T0#'#��������������������������������������������HHKHH���JHHHE�B�O3$66$%&�;75I'#������������������������������������������������������HJKFL���JHGHE�B�Q7#'30.+'�O6'5$71$+*�������������������������������������������������HJKFL���NHNRH�B�=#.5I/#$P'#�8$&3*���������������������������������������������������HJKFL���NHNRJ�B�=#.5I/#$P'#�V'/$.X��������������������������������������������������HNKMF���NHNRN�B�=#.5I/#$P'#�W'7P[���������������������������������������������������HGKNN���NHNRG�B�=#.5I/#$P'#�=#75*0#B=#7$1'#�����������������������������������������HMKHG�

!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!�"#$%&�'(%)*$+,%�-./%.�0'-1�23456�'7$89:+7;+<=�>8+/�?+)@�A%8,%�B#.�C%/%.8:��D#<$.8)$#.7�8EE:+%7�$#�8::�)#<$.8)$7�7*9F%)$�$#�$;%�?%.,+)%�D#<$.8)$�G)$�B#.�H;+);��$;%�)#<$.8)$�+7�8H8./%/�08</�8<I�7#:+)+$8$+#<�H87�+77*%/1�#<�#.�8B$%.�J8<*8.I�2��K524L��MB�$;+7�)#<$.8)$�+7�)#,%.%/�9I�$;%�'-�$;%�)#<$.8)$#.�N*7$�E.#,+/%�%NE:#I%%7��H+$;�2�;#*.�#B�E8+/�7+)@�:%8,%�B#.�%,%.I�35�;#*.7�$;%I�H#.@�*E�$#�O6�;#*.7�#B�E8+/��7+)@�:%8,%�%8);�I%8.L�'NE:#I%%7�N*7$�9%�E%.N+$$%/�$#�*7%�E8+/�7+)@�:%8,%�B#.�$;%+.��#H<�+::<%77�+<F*.I�#.�#$;%.�;%8:$;P.%:8$%/�<%%/7�+<):*/+<=�E.%,%<$+,%�)8.%Q�$#��877+7$�8�B8N+:I�N%N9%.�0#.�E%.7#<�H;#�+7�:+@%�B8N+:I�$#�$;%�%NE:#I%%1�H;#�+7�+::��+<F*.%/�#.�;87�#$;%.�;%8:$;P.%:8$%/�<%%/7�+<):*/+<=�E.%,%<$+,%�)8.%Q�#.�B#.��.%87#<7�.%7*:$+<=�B.#N�#.�$#�877+7$�8�B8N+:I�N%N9%.�0#.�E%.7#<�H;#�+7�:+@%�B8N+:I��$#�$;%�%NE:#I%%1�H;#�+7�$;%�,+)$+N�#B�/#N%7$+)�,+#:%<)%�7%(*8:�8778*:$�#.��7$8:@+<=L��G//+$+#<8:�+<B#.N8$+#<�#<�)#<$.8)$#.�.%R*+.%N%<$7�8</�H#.@%.�E.#$%)$+#<7��*</%.�$;%�'-�+7�8,8+:89:%�8$�HHHL/#:L=#,SH;/S=#,)#<$.8)$7L�GAA�-DDT>GUM-"?�AM?U'V�GW-X'�Y'D'MX'�UZ'�C-AA-[M"\�W'"'CMU?&��Z'GAUZ�]�['ACGY'&�̂_L65�E%.�;#*.�*E�$#�_5�;#*.7�E%.�H%%@�#.�̂2̀_L55�E%.�H%%@�#.��4̂a4L33�E%.�N#<$;���Z'GAUZ�]�['ACGY'�'-�23456&�̂_LK3�E%.�;#*.�*E�$#�_5�;#*.7�E%.�H%%@�#.�̂26aLK5�E%.��H%%@�#.�̂433LK5�E%.�N#<$;b���bU;+7�.8$%�+7�$#�9%�*7%/�#<:I�H;%<�)#NE%<78$+<=�%NE:#I%%7�B#.�E%.B#.N8<)%�#<�8<�?DGP�)#,%.%/�)#<$.8)$�8:7#�)#,%.%/�9I�'-�23456�'7$89:+7;+<=�>8+/�?+)@�A%8,%�B#.�C%/%.8:��D#<$.8)$#.7L��G�)#<$.8)$#.�N8I�<#$�.%)%+,%�).%/+$�$#H8./�+$7�?DG�#9:+=8$+#<7�B#.�8<I��E8+/�7+)@�:%8,%�E.#,+/%/�E*.7*8<$�$#�'-�23456L�XGDGUM-"&�K�H%%@7�E8+/�,8)8$+#<�8B$%.�2�I%8.�#B�7%.,+)%�H+$;�8�)#<$.8)$#.�#.��7*))%77#.�3�H%%@7�8B$%.�25�I%8.7�8</�_�H%%@7�8B$%.�2O�I%8.7L�A%<=$;�#B�7%.,+)%��+<):*/%7�$;%�H;#:%�7E8<�#B�)#<$+<*#*7�7%.,+)%�H+$;�$;%�E.%7%<$�)#<$.8)$#.�#.��7*))%77#.�H;%.%,%.�%NE:#I%/�8</�H+$;�$;%�E.%/%)%77#.�)#<$.8)$#.7�+<�$;%��E%.B#.N8<)%�#B�7+N+:8.�H#.@�8$�$;%�78N%�C%/%.8:�B8)+:+$IL��0?%%�Ka�DCY�_L2431�Z-AMVGc?&�G�N+<+N*N�#B�%:%,%<�E8+/�;#:+/8I7�E%.�I%8.&��"%H�c%8.d7�V8I�e8.$+<��

"#$%&'�()*+�,'-./�0)'$%123�42/%)*+$5*./�0)'$%123�6&75')28�923�,#*&$&&*$%��:2$)5*28�;*1&<&*1&*=&�923�;*1&<&*1&*=&�923�"2>5'�923�?58#7>#/�923�@&$&'2*/.��923�A%2*B/+)C)*+�923�2*1�?%')/$72/�923-�DE�=5*$'2=$5'�723�/#>/$)$#$&�F5'�2*3�5F��$%&�*27&1�%58)123/�2*5$%&'�123�5FF�G)$%�<23�)*�2==5'12*=&�G)$%�2�<82*�=577#*)=2$&1��$5�$%&�&7<853&&/�)*C58C&1-H��DI&&�JK�?LM�N-OPNH�AQR�S??TUEA;S:I�4Q;?Q�QE@R�:T60RMR9�LSSA:SARI�;:�UEMR:AQRIRI�MR?R;@R�AQR�LS""S4;:VW�OH��M2$&/�2'&�2<<8)=2>8&�5*83�#*1&'�$%&�2<<'5<')2$&�5==#<2$)5*28�=2$&+5'3-�XX�T:;LSM6�E""S4E:?R�XX�;F�&7<853&&/�2'&�'&Y#)'&1�$5�G&2'�#*)F5'7/�)*�$%&�<&'F5'72*=&�5F�$%)/�=5*$'2=$��D&)$%&'�>3�$%&�$&'7/�5F�$%&�V5C&'*7&*$�=5*$'2=$�>3�$%&�&7<853&'�>3�$%&�/$2$&�5'��85=28�82G�&$=-H�$%&�=5/$�5F�F#'*)/%)*+�/#=%�#*)F5'7/�2*1�72)*$2)*)*+�D>3��82#*1&')*+�5'�1'3�=8&2*)*+H�/#=%�#*)F5'7/�)/�2*�&Z<&*/&�$%2$�723�*5$�>&�>5'*&�>3�2*��&7<853&&�G%&'&�/#=%�=5/$�'&1#=&/�$%&�%5#'83�'2$&�>&85G�$%2$�'&Y#)'&1�>3�$%&�G2+&��1&$&'7)*2$)5*-�A%&�9&<2'$7&*$�5F�"2>5'�G)88�2==&<$�<237&*$�)*�2==5'12*=&�G)$%�$%&��F5885G)*+�/$2*12'1/�2/�=57<8)2*=&WA%&�=5*$'2=$5'�5'�/#>=5*$'2=$5'�)/�'&Y#)'&1�$5�F#'*)/%�288�&7<853&&/�G)$%�2*��21&Y#2$&�*#7>&'�5F�#*)F5'7/�G)$%5#$�=5/$�5'�$5�'&)7>#'/&�&7<853&&/�F5'�$%&�2=$#28��=5/$�5F�$%&�#*)F5'7/-��;*�211)$)5*�G%&'&�#*)F5'7�=8&2*)*+�2*1�72)*$&*2*=&�)/�721&��$%&�'&/<5*/)>)8)$3�5F�$%&�&7<853&&�288�=5*$'2=$5'/�2*1�/#>=5*$'2=$5'/�/#>[&=$�$5��$%)/�G2+&�1&$&'7)*2$)5*�/%288�D)*�$%&�2>/&*=&�5F�2�>5*2�F)1&�=588&=$)C&�>2'+2)*)*+��2+'&&7&*$�<'5C)1)*+�F5'�2�1)FF&'&*$�275#*$�5'�$%&�F#'*)/%)*+�5F�=5*$'2'3��2FF)'72$)C&�<'55F�2/�$5�$%&�2=$#28�=5/$H�'&)7>#'/&�288�&7<853&&/�F5'�/#=%�=8&2*)*+��2*1�72)*$&*2*=&�2$�2�'2$&�5F�\]-]̂�<&'�G&&B�D5'�\-_P�=&*$/�<&'�123H-��Q5G&C&'�)*��$%5/&�)*/$2*=&/�G%&'&�$%&�#*)F5'7/�F#'*)/%&1�2'&�721&�5F�̀ G̀2/%�2*1�G&2'̀ �̀�72$&')28/�723�>&�'5#$)*&83�G2/%&1�2*1�1')&1�G)$%�5$%&'�<&'/5*28�+2'7&*$/�2*1�15��*5$�'&Y#)'&�2*3�/<&=)28�$'&2$7&*$�/#=%�2/�1'3�=8&2*)*+�12)83�G2/%)*+�5'�=577&'=)28��82#*1&')*+�)*�5'1&'�$5�7&&$�$%&�=8&2*8)*&//�5'�2<<&2'2*=&�/$2*12'1/�/&$�>3�$%&�$&'7/��5F�$%&�V5C&'*7&*$�=5*$'2=$�>3�$%&�=5*$'2=$5'�>3�82G�5'�>3�$%&�*2$#'&�5F�$%&�G5'B��

!"#$#�%&�'(�$#)*%$#+#'!�!",!�#+-.(/##&�0#�$#%+0*$&#1�2($�*'%2($+�+,%'!#','3#�3(&!&4�55�6789:;7�;<=>8?;>�?;>�@:87;><8A�<B�<;;CD?>:<=6�55�>"#�1*!%#&�(2�#+-.(/##&�*'1#$�E(0�!%!.#&�.%&!#1�,$#�!"(&#�1#&3$%0#1�%'�!"#��FF6#$G%3#�;('!$,3!�?3!�@%$#3!($/�(2�<33*-,!%('&FF�B%2!"�71%!%('�H8#G%&%('�IJ��1,!#1�6#-!#+0#$�KLIM�*'.#&&�(!"#$N%&#�%'1%3,!#14���87OC76>�B<8�?C>P<8:Q?>:<=�<B�?@@:>:<=?R�;R?66:B:;?>:<=�?=@�S?T7�8?>7�6!,'1,$1�B($+�IUUU�H6BVIUUUJ�;('2($+,'3#�D$(3#&&W�>"#�3('!$,3!%'X�(22%3#$�&",..�$#)*%$#�!",!�,'/�3.,&&�(2�&#$G%3#�#+-.(/##�N"%3"�%&��'(!�.%&!#1�"#$#%'�,'1�N"%3"�%&�!(�0#�#+-.(/#1�*'1#$�!"#�3('!$,3!�H%4#4�!"#�N($Y�!(��0#�-#$2($+#1�%&�'(!�-#$2($+#1�0/�,'/�3.,&&%2%3,!%('�.%&!#1�%'�!"#�N,X#��1#!#$+%',!%('J�0#�3.,&&%2%#1�0/�!"#�3('!$,3!($�&(�,&�!(�-$(G%1#�,�$#,&(',0.#��$#.,!%('&"%-�H%4#4�,--$(-$%,!#�.#G#.�(2�&Y%..�3(+-,$%&('J�0#!N##'�&*3"�*'.%&!#1��3.,&&%2%3,!%('&�,'1�!"#�3.,&&%2%3,!%('&�.%&!#1�%'�!"#�N,X#�1#!#$+%',!%('4�6*3"��3('2($+#1�3.,&&#&�(2�#+-.(/##&�&",..�0#�-,%1�!"#�+('#!,$/�N,X#&�,'1�2*$'%&"#1�!"#��2$%'X#�0#'#2%!&�,&�,$#�1#!#$+%'#1�H6##�KZ�;B8�U4[H0JHKJH%JJ4�6*3"�3('2($+%'X��-$(3#1*$#&�&",..�0#�%'%!%,!#1�0/�!"#�3('!$,3!($�-$%($�!(�!"#�-#$2($+,'3#�(2�3('!$,3!��N($Y�0/�&*3"�*'.%&!#1�3.,&&H#&J�(2�#+-.(/##&�H6##�KZ�;B8�U4[H0JHKJH%%JJ4�>"#�S,X#��,'1�P(*$�@%G%&%('�&",..�+,Y#�,�2%',.�1#!#$+%',!%('�(2�3('2($+#1�3.,&&%2%3,!%('�N,X#��$,!#�,'1\($�2$%'X#�0#'#2%!&�N"%3"�&",..�0#�$#!$(,3!%G#�!(�!"#�3(++#'3#+#'!�1,!#�(2��!"#�3('!$,3!�H6##�KZ�;B8�U4[H0JHKJH%GJH;JHG%JJ4�S"#'�+*.!%-.#�N,X#�1#!#$+%',!%('&��,$#�%'3.*1#1�%'�,�3('!$,3!�,�&#-,$,!#�6BVIUUU�&"(*.1�0#�-$#-,$#1�2($�#,3"�N,X#��1#!#$+%',!%('�!(�N"%3"�,�3.,&&H#&J�%&�!(�0#�3('2($+#14�>"#�-$(3#&&�2($�-$#-,$%'X�,�3('2($+,'3#�$#)*#&!�%&�,&�2(..(N&W�IJ�S"#'�-$#-,$%'X�!"#�0%1�!"#�3('!$,3!($�%1#'!%2%#&�!"#�'##1�2($�,�3('2($+#1��(33*-,!%('H&J�,'1�3(+-*!#&�,�-$(-(&#1�$,!#H&J4�

!"�#$%&'�()*%'+(%�+,+'-�%.&�()*%'+(%)'�/'&/+'&0�+�,'1%%&*�'&/)'%�210%1*3�1*�)'-&'��%.&�/')/)0&-�(2+001$1(+%1)*�%1%2&40"�+�5&-&'+2�3'+-&�&6718+2&*(9�45:;"�$)'�&+(.��/')/)0&-�(2+001$1(+%1)*40"�<)=�-&0('1/%1)*40"�+*-�'+%1)*+2&�$)'�/')/)0&-�,+3&��'+%&40"�1*(27-1*3�1*$)'>+%1)*�'&3+'-1*3�%.&�+3'&&>&*%�)'�-10+3'&&>&*%�)$�%.&��+7%.)'1?&-�'&/'&0&*%+%18&�)$�%.&�&>/2)9&&0�1*8)28&-�)'�,.&'&�%.&'&�10�*)�+7%.)'1?&-��'&/'&0&*%+%18&�%.&�&>/2)9&&0�%.&>0&28&0@�A.10�'&/)'%�0.)72-�=&�07=>1%%&-�%)�%.&��()*%'+(%1*3�)$$1(&'�*)�2+%&'�%.+*�BC�-+90�+$%&'�07(.�7*210%&-�(2+004&0"�)$�&>/2)9&&0��/&'$)'>0�+*9�()*%'+(%�,)'D@�B"�A.&�()*%'+(%1*3�)$$1(&'�'&81&,0�%.&�/')/)0&-�+(%1)*�+*-�/')>/%29�07=>1%0�+�'&/)'%��)$�%.&�+(%1)*�%)3&%.&'�,1%.�%.&�+3&*(9E0�'&()>>&*-+%1)*0�+*-�/&'%1*&*%��1*$)'>+%1)*�1*(27-1*3�%.&�/)01%1)*�)$�%.&�()*%'+(%)'�+*-�%.&�&>/2)9&&0�%)�%.&�F+3&��+*-�G)7'�H18101)*�I@J@�H&/+'%>&*%�)$�K+=)'�$)'�'&81&,�4J&&�!L�M5N�O@P4="4!"411""@�O"�F1%.1*�BC�-+90�)$�'&(&1/%�%.&�F+3&�+*-�G)7'�H18101)*�+//')8&0�>)-1$1&0�)'��-10+//')8&0�%.&�+(%1)*�81+�%'+*0>1%%+2�%)�%.&�+3&*(9�()*%'+(%1*3�)$$1(&'�)'��*)%1$1&0�%.&�()*%'+(%1*3�)$$1(&'�%.+%�+--1%1)*+2�%1>&�,122�=&�'&671'&-�%)�/')(&00��%.&�'&67&0%@�Q"�A.&�()*%'+(%1*3�)$$1(&'�%'+*0>1%0�%.&�F+3&�+*-�G)7'�-&(101)*�%)�%.&�()*%'+(%)'@�P"�A.&�()*%'+(%)'�1*$)'>0�%.&�+$$&(%&-�&>/2)9&&0@�R*$)'>+%1)*�'&671'&-�=9�%.&�N&372+%1)*0�>70%�=&�07=>1%%&-�)*�J5STOOO�)'�=)*-�/+/&'@�F.&*�/'&/+'1*3�+�()*$)'>+*(&�'&67&0%�%.&�UUJ&'81(&�M)*%'+(%�#(%�H1'&(%)'9�)$��V((7/+%1)*0UU�4%.&�H1'&(%)'9"�0.)72-�=&�70&-�%)�()>/+'&�<)=�-&$1*1%1)*0�%)�&*07'&��%.+%�-7%1&0�'&67&0%&-�+'&�*)%�/&'$)'>&-�=9�+�(2+001$1(+%1)*�+2'&+-9�210%&-�1*�%.&��,+3&�-&%&'>1*+%1)*@�N&>&>=&'�1%�10�*)%�%.&�<)=�%1%2&�=7%�%.&�'&671'&-�%+0D0�%.+%��-&%&'>1*&�,.&%.&'�+�(2+00�10�1*(27-&-�1*�+*�&0%+=210.&-�,+3&�-&%&'>1*+%1)*@��M)*$)'>+*(&0�>+9�*)%�=&�70&-�%)�+'%1$1(1+229�0/21%�()>=1*&�)'�07=-181-&��(2+001$1(+%1)*0�210%&-�1*�%.&�,+3&�-&%&'>1*+%1)*@U���������

Attachment H

URINALYSIS PROCEDURES

Testing Summary:

The Residential Reentry Management Branch is aligning the drug and Alcohol Testing Surveillance Program with the BOP institutions Drug and Alcohol Testing Surveillance Program. This attachment provides detailed instruction for the Residential Re-entry Centers.

• All urine testing will be conducted on an unscheduled basis in accordance with urinalysis procedures.

• The drug and alcohol testing surveillance program can utilize laboratory-based testing for screening and confirmations OR on-site test cups for screening at the point of collection and laboratory-based confirmation testing for any screen positive at the point of collection.

On-Site Test Cup

The manufacturer of the on-site test cups must be an FDA

Licensed Medical Device Manufacturer. The contractor will maintain certification documents and evidence that the manufacturer meets all specifications in Attachment H2 – On-site

Test Cup Maximum Screening Cut-Off Level.

1. Basic Screen Procedures

On-site Test Cup Screening Tests - The cup must be constructed of clear plastic with a screw top lid which will not leak during air/ground shipping. The test cup must be integrated to allow for collection and testing of urine for multiple drugs simultaneously, without a separate testing device. Once the specimen is collected and the lid installed on the cup, no other manipulation of the urine is required such as pouring, tipping, tilting, turning, inserting, and turning a key, or inserting a test card, pipette, dropper, or dipper.

The on-site test cup must have the capability of detecting a minimum of fourteen (14) different drugs at the same time. The

BOP requires, at a minimum, a 14-panel cup with the designated drugs outline in ATTACHMENT H2: On-site Test Cup Screening

Cutoff Levels and Laboratory-Based Confirmation Testing Levels.

The BOP reserves the right to change and specify the type of drugs/test strips and cut-off levels which will be integrated into the on-site test cup based on the facility's resident drug abuse history and regional trends. If a change is necessary, the

BOP will provide 90 days advance notice of the change and an additional 30 days to implement the change.

The on-site test cup must have a minimum fill line (at least

30mL) clearly displayed on the outside of the cup to ensure sufficient specimens are collected.

The cup must have a temperature label on the cup, which provides color-coded indication for temperatures ranging from 90◦F/32◦C to 100◦F/38◦C in 1- or 2-degree increments.

A label or other pull strip in order to conceal the results from residents at the time of testing and shall not leave a residue or otherwise make the test panel unreadable shall cover the test panel results. The test results must appear within five minutes, then remain stable, and be accurately read up to 30 minutes after the specimen is provided in the cup.

Each sterile on-site test cup will be provided in a sealed bag with a lot number, an expiration date, the drugs/cut-off levels the on-site test cup tests for, desiccant, which maintains relative humidity inside the sealed bag within the manufacturer’s recommended specifications, and instructions for use of the on-site test cups on outside of the bag. The product must have a minimum shelf life of 12 months from the date of manufacture.

The contracted Laboratory supplied Chain of Custody forms shall consist of two (2) self-carbonized parts (an original and one copy). Contract staff will use the forms to record the positive specimen identification information, retain the copy, and send the original to the confirmation lab, along with the urine specimen.

2. Confirmation of Positive Tests

On-site Test Cups - For all test cups that read positive and require lab confirmation, the laboratory will provide an identification label (with unique specimen identification number) to seal the lid of the cup, a 2-ply donor resident chain of custody form with preprinted and matching specimen identification number, and a sealable 2-pouch clear shipping bag.

3. Test Panels, Sensitivity and Accuracy

To prevent reagent leaching, each drug test (one drug per strip) must be in its own individual test strip chamber/channel must have a control line indicator to determine if the test has functioned properly.

The manufacturer must ensure the contractor is provided with an up-to-date list of cross-reacting drugs, which will be detected by the on-site test cup. Manufacturer must also provide a list of drugs, which will not be detected and will not produce a positive result for the category of drugs specified in

Attachment H2.

The on-site test cups must have an accuracy rate of at least 97% as compared to screening tests by DHHS certified Enzyme

Multiplied Immunoassay Technique (EMIT) or other DHHS certified comparable testing technology (CERT). Results and documentation must be provided to verify independent tests have been conducted to obtain those accuracy rates. The accuracy rate must not change due to collection site elevation/altitude or humidity levels.

4. Support

The manufacturer must be able to provide free training twice per year for contract staff administering the test, at the request of any RRC contractor for which the cups are provided. This may be accomplished through on-site visits or through video teleconferencing. The manufacturer may provide a training video available to the RRC contractor.

The manufacturer must be able to provide technical assistance as needed by the RRC contactor.

For security purposes, and to maintain the integrity of the testing program, the product being offered must not be sold over the counter or over the internet.

The manufacturer will provide subject matter expert testimony upon request from the RRC contractor to address issues such as testing methodologies, testing results, testing cut-off levels, accuracy of on-site test cups, and other issues.

5. Quality Control/Manufacturing Practices

The RRC must ensure that the manufacturer of the on-site test cups provides a quality and properly functioning product. The manufacturer shall abide by all applicable federal laws and regulations.

6. Other Requirements

The laboratory must perform the confirmation test within 48 hours of receipt. Urine specimens testing positive must be retained by the laboratory for minimum of 30 days for possible retesting, if requested.

Urinalysis Laboratory-Based Services

1. URINALYSIS TESTING SPECIFICATIONS

The laboratory must comply with all specifications contained herein and all applicable local, state, and federal law, as indicated in 42 CFR Part 493, Laboratory Requirements, to engage in urine drug testing for federal residents. The RRC contractor will maintain certification documents and evidence the laboratory meets all specifications in Attachment H1 & H2. The urinalysis laboratory will detect and identify the drugs and/or metabolites by basic screen and confirmation at the minimal levels or lower as shown in Attachment H1 & H2.

Urine samples submitted for testing will contain the laboratory’s required minimum amount of urine, ordinarily 30 milliliters.

A positive written report from the laboratory for any of the drugs listed in Attachment H1 & H2 indicates that the particular drug has been identified by an initial screening test as positive and then confirmed by a laboratory confirmation methodology procedure.

Retesting at the Resident’s request is not permitted.

If necessary, due to litigation, the laboratory must provide a qualified expert witness to testify as to laboratory procedures employed as well as to accuracy and reliability of test results.

Additionally, the laboratory must be able to prove chain of custody. RRMs will review these findings during monitoring visits.

2. Specifications of Methodology Sensitivity - The laboratory will have the capability to detect and identify certain drugs and metabolites by basic screen at minimal levels, or lower, as indicated in the screening test levels.

3. Basic Screening Procedures

a) Laboratory-Based Screening Tests - All laboratory-based primary initial screen tests will be by Department Health and Human Services (DHHS) certified Enzyme Multiplied

Immunoassay Technique (EMIT) or other DHHS certified comparable testing technology (CERT) as indicated in

Attachment H1. All testing will be performed according to manufactures specifications for all requests and instruments, as in FDA approved package inserts or appropriate manufacturer accreditation body which has reviewed and accepted the laboratories modified protocol.

b) Confirmation of Positive Tests - The approved methods of confirmation of specimens testing positive are listed in

Attachment H1 & H2. Confirmation tests must be completed on all initial screen-positives. The confirmation testing shall be capable of providing quantitative information and confirmation levels as specified in Attachment H1 & H2 of this Statement of Work. Examples of scientifically recognizes DHHS methods of testing are Gas

Chromatography/Mass Spectrometry (GC/MS), Gas

Chromatography/Tandem Mass Spectrometry (GC/MS/MS), two-dimensional Gas Chromatography/Mass Spectrometry (GC/MS/MS) or LC/Tandem Mass Spectrometry (LC-MS/MS). No substitutions can be made to the methods.

c) Confirmation Only Test Panels and Sensitivity – The Chain of Custody form, which will accompany each specimen sent by the RRC contractor, will indicate the drug(s) the RRC contract staff is requesting confirmation. The RRC

Contractor may request confirmation for more than one drug from a single on-site test cup specimen. Confirmation will be accomplished for drugs at the lowest cut-off level scientifically possible by the laboratory’s instrumentation and will not be higher than the specified levels listed in

Attachment H2.

d) Special Screening Tests and Follow-up Confirmation Tests – Occasionally, an RRC Contractor may request special screening tests, with some requiring follow-up confirmation tests for any one or even all of the drugs listed in

Attachment H1, as well as steroids, at the minimum cut-off levels or lower.

The drug(s) to be screened for will be indicated on the

Chain of Custody form checked under other and the drug to be tested written in the blank space. If an RRC Contractor requests special screening be conducted for other than those listed in Attachment H1, the RRC Contractor will contact the laboratory to request the special screening test. A scientifically recognized DHHS method of testing, or Enzyme Multiplied Immunoassay Technique (EMIT), or other

DHHS certified comparable testing technology (CERT) will be used as the initial screening method.

The absence of identification of which drugs to be screened and/or confirmed on the Chain of Custody forms does not constitute a “no test”.

4. Other Requirements The laboratory must perform the test within 48 hours of receipt. Urine specimens testing positive must be retained by the laboratory for minimum of 30 days for possible retesting, if requested.

5. Special Tests The laboratory must have the capability to conduct steroid testing and will provide the RRC Contractor with a list of those steroids which the laboratory is certified to test for and the cut-off levels upon request.

6. Laboratory-Based Testing/Screening Procedures

a) Adulteration: All laboratory-based screening specimens, including special testing requests, submitted by an RRC contractor shall be automatically screened for adulteration, substitution, and dilution using DHHS certified laboratory procedures for measuring specific gravity, creatine, and pH. The laboratory must report to the RRC Contractor, any specimen suspected of adulteration and the suspected means or procedure used to adulterate the specimen.

If the laboratory suspects a urine sample contains an adulterant; for example, urine sample smells like bleach or contains foreign objects or discoloration, the RRC Contractor does not expect the lab to perform confirmation testing.

However, the laboratory shall submit a report to the RRC

Contractor’s Facility Director via email informing the RRC

Contractor of the laboratory’s findings.

b) Retest: The RRC Contractor may request the laboratory to retest a specimen previously tested and reported.

c) Quality Control: The BOP reserves the right to conduct random announced/unannounced visits to the laboratory, using an industry recognized contractor/person(s) considered to be an expert in the field of laboratory urine testing, to ensure proper NLCP or CAPDT testing procedures are being followed. The laboratory must be certified in accordance with NLCP or CAPDT rules and regulations and documentation of the certification will be provided.

7. Reporting of Results At the completion of the laboratory tests, the laboratory shall send the originating RRC Contractor facility the results, both negative and positive, within 24 hours via email in a PDF format.

The laboratory may also make test results available to the designated staff by way of a secured web site. Results will be maintained in a database by the laboratory for a minimum three years.

Each urine specimen will require an individual report, or secure web site entry, from the laboratory regarding the results, indicating whether drugs were present or not (positive or negative), based on the cut-off levels stated in Attachment H1 &

H2 of this attachment, and the type of drug(s).

Each result report, or secure web site entry, will have at a minimum, the name of the RRC Contractor Facility, the unique specimen identification number which is on the Chain of Custody form and on the seal of the on-site test cup lid, type of specimen tested, the drugs which were tested and/or screened and tested for, the positive or negative results of those tests, positive results will be displayed with quantitative values, reason for no test if applicable, date and time of collection, receipt of specimen in the laboratory and laboratory result reporting.

8. Retention of Negative Urine Specimens The RRC may request the lab to retain all urine specimens sent in for screening, confirmation testing, or both, which confirm negative to be retained for seven days after the 24-hour notification of the results. This will allow the RRC Contractor to request a retest of the sample.

9. Retention of Positive Urine Specimens Specimen confirmed positive by a scientifically recognized DHHS method of testing shall be retained for a minimum 60 days by the laboratory in appropriate storage ensuring the specimen is preserved in a condition suitable for retesting.

The laboratory shall maintain all positive reports for a period of 3 years.

10. No Test Criteria

Examples of conditions, which warrant a “no test” condition from the laboratory, are:

a) Specimens without the minimum amount of urine required to complete a proper test due to leakage, which occurred during shipment or insufficient level of urine provided by the donor resident.

If leakage is noted, every attempt will be made to conduct the requested test with the remaining urine in the cup or using the urine, which may have leaked but still contained in the sealed two-part bio bag and/or by extracting the urine from the absorbent pad in the bio bag.

b) Specimen with a tampered seal (the tamper-resistant seal must be intact for testing to be performed).

c) Specimens with tamper-resistant seals not dated and initialed by the donor resident (tamper-resistant seals must be initialed and dated for testing to be performed).

d) Specimens that the RRC Contractor requests confirmation test only and the laboratory determines the specimen visibly appears adulterated, diluted, or substituted will be screened/tested accordingly as outline in Laboratory-Based Testing/Screening

Procedures – Adulteration, but will not be screened for any other drugs or steroids.

If the adulteration test proves positive, this will be declared a “no test” because the confirmation testing could not be conducted.

e) Specimens which indicate a negative result at the testing site, but the RRC Contractor has sent in for further screening and confirmation request will be automatically screened for adulteration, dilution, and/or substitution.

If this test produces a positive result for adulteration, this will be declared a “no test” since the screening for the drugs and/or steroids, depending on the institution’s request, could not be completed.

f) The laboratory shall report each “no test” and the specific reason back to the RRC Contractor in the same manner as reporting the positives and negative results as outlined in

Reporting Results.

g) A Chain of Custody form not completely filled out does not constitute a “no test” criteria. Even if no information is filled out on the form, the laboratory will still have the pre-printed RRC Contractor Name and Address, the account number, and the unique specimen ID number to send the results back to the

RRC Contractor Facility.

If the RRC Contractor failed to identify on the form, the confirmation tests required and/or special screening and confirmation test required, then the laboratory will conduct screening and confirmation for all the drugs and the cut-off levels as outlined in Attachment A, and report those results to the requesting RRC Contractor.

11. Standard Procedures for Collecting Urine Surveillance

Samples – Laboratory-Based or On-site Test Cup

a. Staff of the same gender as the resident being tested will directly supervise the giving of the urine sample. To eliminate the possibility of a diluted or adulterated sample, staff will keep the resident under direct visual observation until a complete sample is furnished.

If the resident is unable to provide the sample, at the time of the request, staff will continue direct supervision for a two-hour period. To assist the resident in giving the sample, staff will offer the resident sufficient water (minimum of 12 oz.)

during the two-hour time period to aid in urination.

If a resident is unwilling or unable to provide a urine sample within two hours of a request, staff will file an incident report. No waiting period or extra time will be allowed for a resident who directly and specifically refuses to provide a urine sample.

Staff will visually witness the collection of urine into the specimen container. As soon as the sample has been collected, staff will secure the specimen. No unauthorized persons or residents may be involved in the handling of supplies or the collecting, recording, mailing, or processing of test results under any circumstances.

If an on-site test cup is utilized for the screening test, it is allowable for the on-site test cup to be used as a collection cup, on-site screening test and transportation cup to the laboratory in the event of a screen positive on the on-site screening test device.

On-site screening test will not be used as the sole evidence in issuing an incident report for positive use. An incident report should not be issued until a final laboratory report of a confirmation test is reported.

b. Residents will be thoroughly searched to detect any device designed to provide a urine substitute or possible contaminant and will thoroughly wash their hands prior to providing a sample.

c. Urine samples will be kept under direct RRC Contractor staff observation and control at all times, both before and after the donor resident furnishes the urine sample until moved to a secured area where the urine samples will be stored until mailing. This area should be designated by the Facility Director and will be accessible to a very limited number of RRC

Contractor staff. Under no circumstances will residents have access to this area.

d. All urine samples will be mailed to the testing laboratory no later than 24 hours after collection, (excluding holidays and weekends).

e. Each RRC Contracted facility will maintain a Drug Test Log documenting all urine testing and will be available for review by the RRM when requested. The log will indicate donor resident name, RRC Contractor staff (collector) name, date of collection, time of collection, type of test performed, test result and if resident refused to cooperate.

f. When the resident reports for testing RRC Contractor staff will:

(1)Make a positive picture identification of the resident;

(2)Donor Resident will thoroughly wash their hands;

(3)Collect the sample from resident under direct observation;

(4)Assign the sample a urine sample identification number from the chain of custody form provided by the laboratory;

(5)Seal the urine sample with a bottle label that is affixed to the bottom of the chain of custody form in the presence of the resident donor; have the donor initial and date the bottle label seal ONLY after the label has been affixed to the urine sample;

(6)For a laboratory-based or on-site test cup urine collection, complete the chain of custody form to include, collection site information, collection information (i.e., temperature, observed collection, type of sample collected [single or split], donor printed name, signature and date, collector printed name, signature, and date).

(7)Once Chain of Custody is completed and the on-site test cup device is used, have the resident donor step away from the testing area while the contract staff reads the screening test results. This avoids resident donor/RRC Contractor staff confrontation. The RRC Contractor staff performing the on-site test cup should let the testing device out of their sight anytime during the testing process.

(8) If using the on-site test cup device, and the urine sample is negative, circle the Negative and place the Chain of Custody form in the resident donor’s file as documentation of the drug test; dispose of the urine sample in the toilet and the on-site test cup in the trash can;

(9)If using the on-site test cup device, and the urine sample screens positive for drug(s), indicate on the Chain of Custody form, by checking or circling the drug(s) that the laboratory will perform confirmation testing on.

(10)For laboratory-based or on-site test cup urine samples, place the sealed urine sample in the front pouch of the bio bag and the completed chain of custody form in the back pouch of the bio bag; seal the bio bag and place the sample in a secured area until the urine sample is shipped to the laboratory.

(11)Record the donor resident name, RRC Contractor staff

(collector) name, date, time, type of test performed, test result and if resident refused to cooperate on the Drug Testing

Log.

(12)Positive Tests – For an incident report charging use of a particular drug to be justified, the minimum waiting period between successive positive samples, as outlined below in

Detection Periods for Selected Drugs, must be observed. In addition, waiting periods also apply to residents who initially arrive at the facility.

When a positive result is received, and an incident report written, a photocopy of both the copy of the Chain of Custody form and the positive laboratory report will be attached to the incident report and made a part of the disciplinary record.

When a positive finding cannot be explained, RRC staff will thoroughly investigate the positive urine test result to validate the positive urine test result to validate the positive finding. The RRC Contractor will report all unauthorized positive test results to the RRM on the day received.

Detection Periods for Selected Drugs

The time periods below are estimates of the maximum lengths of time, after last use, that a person’s urine would be positive for a particular drug. These periods also represent the minimum waiting periods between samples on which successive disciplinary actions for the same drug ordinarily may be based.

For example, ordinarily at least 30 days must lapse between urine collection dates before disciplinary action may be taken for a second THC positive. The resident could, however, be retested within this 30-day period and disciplinary action could be based on positive results for drugs other than THC.

Time

Drugs

3 Days Amphetamines, Methamphetamine, Cocaine, Cocaine

Metabolite, Buprenorphine, Fentanyl, K2/Spice

(Synthetic Marijuana), MDPV (Bath Salts)

5 Days Methadone and Methadone Metabolite

6 Days Morphine, Codeine, Opiates, Meperidine (Demerol), Pentazocine (Talwin), Propoxyphene (Darvon), Benzodiazepines Ecstasy (MDMA), Oxycodone

11 Days Barbiturates and Phencyclidine (PCP)

14 Days Phenobarbital

30 Days THC

ATTACHMENT H1: Laboratory Screening and Confirmation Testing

Drug/Substance Screening

Method

Maximum

Cut-Off

Level

Confirmation

Method

Maximum

Cut-Off

Level

Amphetamines

EMIT/CERT 300 ng/mL GC/MS or LC-

MS/MS

75 ng/mL

Barbiturates

(Amorbarbital, Butabarbital, Butalbital, Pentobarbital, Phenobarbital, Secobarbital)

EMIT/CERT

200 ng/mL

GC/MS or LC-

50 ng/mL

Benzodiazepines

(Alprazolam)a

EMIT/CERT 300 ng/mL GC/MS or LC-

MS/MS

25 ng/mL

Cocaine

(Benzoylecgonine)

EMIT/CERT 150 ng/mL GC/MS or LC-

MS/MS

12 ng/mL

THC EMIT/CERT 15 ng/mL GC/MS or LC-

MS/MSA

4 ng/mL

Methamphetamines a

EMIT/CERT 300 ng/mL GC/MS or LC-

MS/MS

75 ng/mL

Morphine a

EMIT/CERT 300 ng/mL GC/MS or LC-

MS/MSA

25 ng/mL

Oxycodone

(Oxymorphone)

EMIT/CERT 300 ng/mL GC/MS or LC-

MS/MS

25 ng/mL

Opiates

(Codeine, Hydrocodone, Hydromorphone)

300 ng/mL

25 ng/mL

Phencyclidine

(PCP)

EMIT/CERT 100 ng/mL GC/MS or LC-

MS/MS

10 ng/mL

MDPV (Bath Salts) a

EMIT/CERT 15 ng/mL GC/MS or LC-

MS/MS

9 ng/mL

Fentanyl

(Nor-Fentanyl)a

EMIT/CERT 2 ng/mL GC/MS or LC-

MS/MS

1 ng/mL

Synthetic

Cannabinoids

(K2/SPICE)a

15 ng/mL

A

LOD

Buprenorphine

(Nor-

Buprenorphine)

EMIT/CERT 5 ng/mL GC/MS or LC-

4 ng/mL

ATTACHMENT H2: On-site Test Cup Screening Cutoff Levels and

Laboratory-Based Confirmation Testing Levels

Drug/Substance

On-site

Test Cup

Maximum

Screening

Cut-Off

Level

Laboratory-Based

Confirmation

Method

Laboratory-

Based

Maximum

Cut-Off

Level

Amphetamines 300 ng/mL GC/MS or LC-

MS/MS

75 ng/mL

Barbiturates

(Amorbarbital, Butabarbital, Butalbital, Pentobarbital, Phenobarbital, Secobarbital)

300 ng/mL

50 ng/mL

Benzodiazepines

(Alprazolam)

200 ng/mL GC/MS or LC-

MS/MS

25 ng/mL

Cocaine

(Benzoylecgonine)

150 ng/mL GC/MS or LC-

MS/MS

12 ng/mL

THC 50 ng/mL GC/MS or LC-

MS/MS

4 ng/mL

Methamphetamines 300 ng/mL GC/MS or LC-

MS/MS

75 ng/mL

Morphine 300 ng/mL GC/MS or LC-

MS/MS

25 ng/mL

Oxycodone

(Oxymorphone)

300 ng/mL GC/MS or LC-

MS/MS

25 ng/mL

Opiates

(Codeine, Hydrocodone, Hydromorphone)

300 ng/mL GC/MS or LC-

MS/MS

25 ng/mL

Phencyclidine

(PCP)

25 ng/mL GC/MS or LC-

MS/MS

10 ng/mL

MDPV (Bath Salts) 300 ng/mL GC/MS or LC-

MS/MS

9 ng/mL

Fentanyl

(Nor-Fentanyl)

100 ng/mL GC/MS or LC-

MS/MS

1 ng/mL

Synthetic

Cannabinoids

(K2/SPICE)

50 ng/mL GC/MS or LC-

MS/MS

LOD

Buprenorphine

(Nor-

Buprenorphine)

10 ng/mL GC/MS or LC-

4 ng/mL